Markets & Finance

J.P. Morgan Raise Invitrogen to 'Overweight'


J.P. Morgan upgraded Invitrogen (IVGN) to overweight from neutral.

Analyst Chris Shibutani says he strongly thinks Invitrogen's plans to acquire Molecular Probes will re-accelerate growth in Invitrogen's molecular biology business and provide meaningful accretion to earnings in 2003 and 2004. He believes Molecular Probes' revenue should benefit significantly from a substantial improvement in distribution capabilities with Invitrogen.

Shibutani says even with Wednesday's stock price increase, the shares still trade at a discount to re-agent supplier peers, a discount that he finds unwarranted.


Tim Cook's Reboot
LIMITED-TIME OFFER SUBSCRIBE NOW

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

 
blog comments powered by Disqus